OS Therapies Incorporated (OSTX) Stock Forecast
OSTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $8.50 average of analyst targets
- Upside to target
- +543.9% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.13
- 52-week range
- $1.16 – $2.24
OSTX analyst ratings
4 analystsNumber of analysts at each rating.
OSTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
OSTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.16 | −$0.10 | −$0.21 | +42.9% | 3 |
| Current fiscal year (2026) | −$0.70 | −$0.75 | −$0.64 | −$1.03 | +32.1% | 3 |
| Next fiscal year (2027) | $0.35 | −$0.22 | $1.40 | −$0.70 | +149.5% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
OSTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (2027) | $26.6M | $0 | $49.0M | 0.0% | 4 |
OSTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
OSTX revenue: reported and forecast
OSTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.20 | −$0.10 | −$0.12 | −$0.12 | −20.0% | 3 up · 0 down |
| Current fiscal year (2026) | −$0.65 | −$0.78 | −$0.68 | −$0.70 | −$0.70 | +8.5% | 2 up · 1 down |
| Next fiscal year (2027) | −$0.22 | $0.36 | $0.32 | $0.35 | $0.35 | −257.6% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
OSTX earnings surprises
Reported EPS vs the consensus estimate for the last 9 quarters; OSTX beat in 1 of 8.
What analysts expect from OSTX
4 analysts cover OS Therapies; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.50, 543.9% above the latest close of $1.32. Analysts expect earnings of −$0.70 per share for 2026, +32.1% from a year earlier. For 2027 the average estimate is $0.35 per share on revenue of $26.6 million. OS Therapies beat the EPS estimate in 1 of the last 8 quarters.
Related: OSTX income statement, OSTX key metrics, OSTX chart. See the OSTX stock overview for the latest quote and news.
OSTX forecast FAQ
What is OS Therapies's price target?
The average analyst price target for OS Therapies is $8.50, 543.9% above the latest close of $1.32.
Is OS Therapies a buy, hold or sell?
Of 4 analysts covering OS Therapies, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is OS Therapies's EPS forecast?
Analysts forecast −$0.70 per share for 2026 (range −$0.75 to −$0.64); for 2027 the estimate is $0.35.
When does OS Therapies report earnings?
OS Therapies is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.13.
Does OS Therapies usually beat earnings estimates?
OS Therapies reported EPS at or above the analyst estimate in 1 of the last 8 quarters.